@article {6016,
	title = {Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women},
	journal = {Maturitas},
	volume = {42},
	year = {2002},
	month = {2002///},
	pages = {77 - 84},
	abstract = {Objective: To study the effect of 17β-estradiol+norethisterone acetate and raloxifene on the endometrium and uterine volume in postmenopausal women. Methods: Patients were randomly assigned to 17β-estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily (n=90) or raloxifene HCl 60 mg (Evista) daily (n=43). Transvaginal sonography was done at baseline and at 6, 12 and 18 months, and at 6 and 12 months in-patients treated with E2+NETA and EVISTA respectively. Patients were asked to record bleeding-spotting episodes. Whenever required patients were referred for hysteroscopy{\textpm}biopsy of the endometrium. Results: Patients under E2+NETA had a higher bleeding-spotting incidence (48.6\%) compared with EVISTA (7.7\%). Endometrial thickness increased significantly under E2+NETA as compared with baseline; however, at end point thickness reverted to baseline values. Evista had a non-stimulatory effect on the endometrium. Changes in uterine volume were not statistically significant. Conclusions: Both treatment regimens provided comparable uterine safety. However, raloxifene exhibited a more favorable safety profile on the uterus as expressed in the bleeding-spotting incidence and the effect on endometrial thickness and uterine volume. Transvaginal sonography appears to be a dependable method for monitoring the effect of treatment on the uterus. {\textcopyright} 2002 Elsevier Science Ireland Ltd. All rights reserved.},
	keywords = {HRT, raloxifene, Sonography, Transvaginal sonographic monitoring},
	author = {Christodoulacos, G. and Panoulis, C. and Botsis, D. and Rizos, D. and Kassanos, D. and Creatsas, G.}
}
